MeiraGTx Holdings plc is a clinical-stage gene therapy company that develops and commercializes transformative treatments for patients suffering from serious diseases. The company's pipeline includes gene therapies for the treatment of inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia.
MeiraGTx's lead product candidate, AAV-RPE65, is a gene therapy for the treatment of inherited retinal diseases caused by mutations in the RPE65 gene. The therapy has shown promising results in clinical trials and is currently being reviewed by regulatory agencies for approval. The company is also developing gene therapies for the treatment of neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).
In addition to its gene therapy pipeline, MeiraGTx is also developing a novel, non-opioid treatment for severe forms of xerostomia, or chronic dry mouth. The company's product candidate, AAV-NGF, is a gene therapy that delivers the nerve growth factor protein directly to salivary glands, with the potential to restore natural saliva production.
MeiraGTx has established collaborations with leading academic institutions, including the University of Massachusetts Medical School and the University of Florida, as well as with industry partners, such as Janssen Pharmaceuticals and Horizon Therapeutics. The company is headquartered in London, UK, with additional locations in New York, NY and Philadelphia, PA.
|
